Piramal Pharma Solutions Achieves Full Regulatory Compliance for Nitrosamine Impurities
核心洞察
Piramal Pharma Solutions has successfully completed its comprehensive action plan to achieve regulatory compliance with global nitrosamine drug substance-related impurities (NDSRI) guidelines.
The company implemented extensive risk assessments, confirmatory testing, and control strategies across all drug substances and products to ensure patient safety.
Significant investments were made in state-of-the-art testing equipment and capabilities at Ahmedabad and Digwal facilities to expedite compliance processes and prevent drug shortages.
Piramal Pharma Solutions, a leading global Contract Development and Manufacturing Organization (CDMO), has successfully achieved regulatory compliance with international guidelines for nitrosamine impurities (搜索) in pharmaceuticals. The milestone represents the completion of a comprehensive, multi-step action plan designed to address evolving regulatory requirements and ensure patient safety.
Comprehensive Compliance Strategy
The company developed a robust approach to tackle the complex challenge of nitrosamine drug substance-related impurities (NDSRIs). Nitrosamines are unintended carcinogenic byproducts (搜索) that can be found in certain medications, and international guidelines surrounding these impurities have evolved significantly over recent years, requiring pharmaceutical companies to adapt their operations to maintain compliance.
Piramal's strategy began with the formation of a cross-functional core team comprising subject matter experts from Regulatory Affairs, Central Quality, R&D, and Manufacturing. This team played a pivotal role in interpreting regulatory guidance and ensuring organizational compliance with international NDSRI guidelines.
The team developed and continually updated a Position Paper, serving as a centralized guidance document aligned with the latest regulatory expectations. By clearly defining roles and responsibilities, this document enabled site teams to adapt to the challenges and changes associated with the new requirements.
Risk Assessment and Testing Implementation
A critical component of the compliance journey involved prioritizing comprehensive risk assessments for all relevant drug substances and drug products to analyze their level of safety and regulatory impact. All identified products received confirmatory testing, with control strategies and administrative controls implemented as needed.
Currently, all existing Piramal Pharma Limited commercial products comply with global regulatory requirements. However, some customer products remain pending approval, and new batches will only be executed following regulatory alignment.
Infrastructure and Capability Enhancements
The action plan included significant investments in developing in-house testing capabilities at key facilities, alongside the qualification of external laboratories to support additional testing needs. The company made substantial investments in new state-of-the-art equipment and capabilities at the Ahmedabad and Digwal pharmaceutical development sites to expedite testing and compliance processes and mitigate potential drug shortage issues.
These enhancements address industry-wide challenges posed by impurity standards and synthesis difficulties, enabling Piramal to synthesize and qualify impurities in-house, minimize impurity formation, and conduct additional screening studies to confirm product safety.
Leadership Perspective
"At Piramal Pharma Solutions, patient well-being is our top priority. We are proud to have achieved regulatory compliance for nitrosamine impurities (搜索), which reflects our unwavering commitment to patient safety and operational excellence, while also solidifying our position as a trusted partner in the industry," said Rashida Najmi, Chief Quality Officer, Piramal Pharma Limited.
Najmi emphasized the company's preparedness for future challenges: "With our proactive approach and enhanced capabilities, we are well-equipped to adapt to evolving global NDSRI standards, ensuring the highest safety and quality standards for our products."
Future Commitment
As international guidelines surrounding nitrosamines continue to evolve, Piramal Pharma Solutions remains committed to patient safety, regulatory compliance, and operational excellence. The company will continue to support partners as they navigate the complex landscape of nitrosamine control, prioritizing transparent communication and continuous improvement to maintain the highest standards of pharmaceutical quality and patient safety.